Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Genzyme, a Sanofi Company
Patients receive infusions of MGBG on days 1 and 8 and every 2 weeks thereafter. It is suggested that a lumbar puncture be performed to evaluate for leptomeningeal disease.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients must have:
HIV positivity by ELISA confirmed by Western blot.
AIDS-related NHL that is refractory or relapsed.
Life expectancy of at least 12 weeks.
You may not be if
Co-existing Condition:
Patients with the following symptoms and conditions are excluded:
Concomitant malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy.
Active uncontrolled bacterial infection, viral infection (other than herpes simplex), or fungal infection (other than oropharyngeal candidiasis) that requires treatment within 2 weeks of study entry.
Significant cardiovascular disease.
Concurrent Medication:
Excluded:
Hormonal therapy (except medications given for muscle wasting, such as testosterone or Megace).
Other chemotherapy.
Investigational anti-cancer drugs.
Concurrent Treatment:
Excluded:
Concomitant radiation to sites other than CNS.
Patients with the following prior conditions are excluded:
Prior malignancy OTHER THAN curatively treated carcinoma in situ of the cervix; basal or squamous cell carcinoma of the skin; or non-active, non-visceral Kaposi's sarcoma not requiring active chemotherapy.
Recommended:
Prophylaxis for PCP and oral candidiasis.
Required in patients with leptomeningeal disease:
Intrathecal methotrexate or cytarabine (Ara-C).
Leucovorin.
Required in patients with leptomeningeal disease:
Cranial radiation to a helmet field.
Clareo Health | A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's Lymphoma
